Allogene Therapeutics Stock Price, News & Analysis (NASDAQ:ALLO) $2.28 -0.30 (-11.63%) (As of 04:30 PM ET) Add Compare Share Share Today's Range$2.25▼$2.7450-Day Range$2.42▼$3.9152-Week Range$2.25▼$10.65Volume4.22 million shsAverage Volume2.09 million shsMarket Capitalization$383.67 millionP/E RatioN/ADividend YieldN/APrice Target$15.35 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Allogene Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside558.6% Upside$15.35 Price TargetShort InterestBearish30.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.10) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector435th out of 949 stocksBiological Products, Except Diagnostic Industry72nd out of 161 stocks 3.3 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.35, Allogene Therapeutics has a forecasted upside of 558.6% from its current price of $2.33.Amount of Analyst CoverageAllogene Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted30.59% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently decreased by 4.97%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLO. Previous Next 1.9 News and Social Media Coverage News SentimentAllogene Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Allogene Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.40% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.51% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to grow in the coming year, from ($2.10) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allogene Therapeutics Stock (NASDAQ:ALLO)Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Read More ALLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLO Stock News HeadlinesNovember 24, 2023 | benzinga.comAllogene Therapeutics Stock (NASDAQ:ALLO) Dividends: History, Yield and DatesNovember 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and LAVA Therapeutics (LVTX)November 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 22, 2023 | msn.comGain Therapeutics (GANX) Down 25% on Issue of New Common StockNovember 19, 2023 | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 8.5%November 16, 2023 | markets.businessinsider.comAllogene Therapeutics Gains Buy Rating: Strong Q3 Financials, Promising Clinical Trials and Catalysts AheadNovember 10, 2023 | finance.yahoo.comAllogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should KnowNovember 6, 2023 | markets.businessinsider.comMaintaining Buy Rating on Allogene Therapeutics: Encouraging Financials, Pipeline, and Therapeutic PotentialNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 6, 2023 | markets.businessinsider.comHold Rating for Allogene Therapeutics Amid Clinical Trials Progress and Financial ConcernsNovember 4, 2023 | markets.businessinsider.comPromising Clinical Trials and Innovative Strategies Bolster Buy Rating for Allogene Therapeutics: An Analysis by John NewmanNovember 3, 2023 | finanznachrichten.deAllogene Therapeutics, Inc.: Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | markets.businessinsider.comPromising Clinical Trials and Future Market Potential Drive Buy Rating for Allogene TherapeuticsNovember 3, 2023 | msn.comAllogene shares rally 22% amid Q3 report, medical meeting presentationsNovember 3, 2023 | finance.yahoo.comAllogene's (ALLO) Q3 Loss Narrower Than Expected, Sales MissNovember 3, 2023 | finance.yahoo.comAllogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual MeetingNovember 3, 2023 | finance.yahoo.comAllogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual MeetingNovember 3, 2023 | finance.yahoo.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comAllogene Therapeutics Inc (ALLO) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comAllogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of HematologyNovember 1, 2023 | benzinga.comEarnings Outlook For Allogene TherapeuticsNovember 1, 2023 | markets.businessinsider.comHere's what Wall Street expects from Allogene Therapeutics's earnings reportOctober 31, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Viridian Therapeutics (VRDN) and Tenet Healthcare (THC)October 29, 2023 | finance.yahoo.comIs Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Deliver On Growth Plans?October 26, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Oric Pharmaceuticals (ORIC), Viking Therapeutics (VKTX)October 16, 2023 | nasdaq.comAllogene Therapeutics Names Geoffrey Parker CFOOctober 16, 2023 | marketwatch.comAllogene Therapeutics Taps Ex-Tricida Executive for CFOSee More Headlines Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLO CUSIPN/A CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees359Year Founded2018Price Target and Rating Average Stock Price Target$15.35 High Stock Price Target$31.00 Low Stock Price Target$6.00 Potential Upside/Downside+558.6%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-332,630,000.00 Net Margins-178,954.28% Pretax Margin-178,954.27% Return on Equity-54.03% Return on Assets-43.69% Debt Debt-to-Equity RatioN/A Current Ratio12.58 Quick Ratio12.58 Sales & Book Value Annual Sales$240,000.00 Price / Sales1,633.72 Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book0.67Miscellaneous Outstanding Shares168,280,000Free Float122,169,000Market Cap$392.09 million OptionableNot Optionable Beta0.83 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Arie S. Belldegrun F.A.C.S. (Age 74)M.D., Co-Founder & Executive Chairman Comp: $714.25kDr. David D. Chang M.D. (Age 63)Ph.D., Co-Founder, President, CEO & Director Comp: $1.1MMr. Joshua A. Kazam (Age 46)Co-Founder & Director Comp: $711kMr. Geoffrey M. Parker (Age 58)Executive VP & CFO Mr. Timothy L. Moore Ph.D. (Age 62)Executive VP & Chief Technical Officer Mr. Earl M. Douglas Esq. (Age 60)General Counsel & Compliance Officer Ms. Susan R. Lundeen (Age 57)Chief People Officer Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy OfficerDr. Zachary J. Roberts M.D. (Age 45)Ph.D., Executive VP of Research & Development and Chief Medical Officer Yinlin ChenSenior Vice President of FinanceMore ExecutivesKey CompetitorsAlectorNASDAQ:ALECProKidneyNASDAQ:PROKAdaptimmune TherapeuticsNASDAQ:ADAPbluebird bioNASDAQ:BLUEOrchard TherapeuticsNASDAQ:ORTXView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 193,776 shares on 11/24/2023Ownership: 0.026%EP Wealth Advisors LLCBought 10,850 shares on 11/24/2023Ownership: 0.006%Creative PlanningBought 33,601 shares on 11/16/2023Ownership: 0.020%Penserra Capital Management LLCBought 7,109 shares on 11/16/2023Ownership: 0.017%GTS Securities LLCBought 10,994 shares on 11/16/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions ALLO Stock Analysis - Frequently Asked Questions Should I buy or sell Allogene Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares. View ALLO analyst ratings or view top-rated stocks. What is Allogene Therapeutics' stock price target for 2024? 11 brokers have issued 12-month price targets for Allogene Therapeutics' shares. Their ALLO share price targets range from $6.00 to $31.00. On average, they anticipate the company's stock price to reach $15.35 in the next twelve months. This suggests a possible upside of 558.6% from the stock's current price. View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts. How have ALLO shares performed in 2023? Allogene Therapeutics' stock was trading at $6.29 on January 1st, 2023. Since then, ALLO shares have decreased by 63.0% and is now trading at $2.33. View the best growth stocks for 2023 here. When is Allogene Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our ALLO earnings forecast. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.16. The company earned $0.04 million during the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics had a negative net margin of 178,954.28% and a negative trailing twelve-month return on equity of 54.03%. What ETFs hold Allogene Therapeutics' stock? ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Simplify Propel Opportunities ETF (SURI), Range Cancer Therapeutics ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX) and What is David Chang's approval rating as Allogene Therapeutics' CEO? 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP). When did Allogene Therapeutics IPO? (ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO. Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), JPMorgan Chase & Co. (4.11%), Primecap Management Co. CA (3.14%), Rafferty Asset Management LLC (0.54%), Barclays PLC (0.47%) and Charles Schwab Investment Management Inc. (0.47%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ALLO) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.